{
  "Covaxin_continents": "Africa, Asia, Europe, and South America",
  "Covaxin_country_count": "31",
  "Sinovac_continents": "Africa, Asia, Europe, North America, and South America",
  "Sinovac_country_count": "66",
  "owid_RNA_count": "2",
  "owid_RNA_countries": "169",
  "owid_RNA_map": "https://github.com/greenelab/covid19-review/raw/491c2e0836dba88e54bb54f8fc38fd7c5593f289/owiddata/maps/RNA.png",
  "owid_VLP_count": "1",
  "owid_VLP_countries": "1",
  "owid_VLP_map": "https://github.com/greenelab/covid19-review/raw/491c2e0836dba88e54bb54f8fc38fd7c5593f289/owiddata/maps/VLP.png",
  "owid_commit_date": "2023-02-11T07:08:01Z",
  "owid_commit_date_pretty": "February 11, 2023",
  "owid_commit_sha": "0a6b73b6204e3086f9ba00208f7d13ec5c9399b9",
  "owid_doses_bargraph": "https://github.com/greenelab/covid19-review/raw/491c2e0836dba88e54bb54f8fc38fd7c5593f289/owiddata/OWID_dosesByContinent.png",
  "owid_doses_scatterplot": "https://github.com/greenelab/covid19-review/raw/491c2e0836dba88e54bb54f8fc38fd7c5593f289/owiddata/OWID_doseTypebyGDP.png",
  "owid_inactivated_count": "10",
  "owid_inactivated_countries": "118",
  "owid_inactivated_map": "https://github.com/greenelab/covid19-review/raw/491c2e0836dba88e54bb54f8fc38fd7c5593f289/owiddata/maps/inactivated.png",
  "owid_most_recent_date": "February 10, 2023",
  "owid_non_replicating_viral_vector_count": "5",
  "owid_non_replicating_viral_vector_countries": "202",
  "owid_non_replicating_viral_vector_map": "https://github.com/greenelab/covid19-review/raw/491c2e0836dba88e54bb54f8fc38fd7c5593f289/owiddata/maps/non_replicating_viral_vector.png",
  "owid_protein_subunit_count": "9",
  "owid_protein_subunit_countries": "43",
  "owid_protein_subunit_map": "https://github.com/greenelab/covid19-review/raw/491c2e0836dba88e54bb54f8fc38fd7c5593f289/owiddata/maps/protein_subunit.png",
  "owid_total_countries": "223",
  "owid_vaccine_counts": "28",
  "owid_worldwide_daily_rate": "131.0 per million",
  "owid_worldwide_date": "February 4, 2023",
  "owid_worldwide_total_vaccinations": "13.0 billion",
  "viper_approved_DNA": "| Vaccine                                      | Company                     | Platform                     |\n|:---------------------------------------------|:----------------------------|:-----------------------------|\n| iNCOVACC                                     | Bharat Biotech              | non replicating viral vector |\n| Convidecia                                   | CanSino                     | non replicating viral vector |\n| Convidecia Air                               | CanSino                     | non replicating viral vector |\n| Gam-COVID-Vac                                | Gamaleya                    | non replicating viral vector |\n| Sputnik Light                                | Gamaleya                    | non replicating viral vector |\n| Sputnik V                                    | Gamaleya                    | non replicating viral vector |\n| Jcovden                                      | Janssen (Johnson & Johnson) | non replicating viral vector |\n| Vaxzevria                                    | Oxford/AstraZeneca          | non replicating viral vector |\n| Covishield (Oxford/ AstraZeneca formulation) | Serum Institute of India    | non replicating viral vector |\n| ZyCoV-D                                      | Zydus Cadila                | plasmid vectored             |",
  "viper_approved_RNA": "| Vaccine                                       | Company                            |\n|:----------------------------------------------|:-----------------------------------|\n| GEMCOVAC-19                                   | Gennova Biopharmaceuticals Limited |\n| Spikevax                                      | Moderna                            |\n| Spikevax Bivalent Original/Omicron BA.1       | Moderna                            |\n| Spikevax Bivalent Original/Omicron BA.4/BA.5  | Moderna                            |\n| Comirnaty                                     | Pfizer/BioNTech                    |\n| Comirnaty Bivalent Original/Omicron BA.1      | Pfizer/BioNTech                    |\n| Comirnaty Bivalent Original/Omicron BA.4/BA.5 | Pfizer/BioNTech                    |\n| TAK-919 (Moderna formulation)                 | Takeda                             |\n| AWcorna                                       | Walvax                             |",
  "viper_approved_subunit": "| Vaccine                                   | Company                                                    | Platform        |\n|:------------------------------------------|:-----------------------------------------------------------|:----------------|\n| Zifivax                                   | Anhui Zhifei Longcom                                       | protein subunit |\n| Noora vaccine                             | Bagheiat-allah University of Medical Sciences              | protein subunit |\n| Corbevax                                  | Biological E Limited                                       | protein subunit |\n| Abdala                                    | Center for Genetic Engineering and Biotechnology (CIGB)    | protein subunit |\n| Soberana 02                               | Instituto Finlay de Vacunas Cuba                           | protein subunit |\n| Soberana Plus                             | Instituto Finlay de Vacunas Cuba                           | protein subunit |\n| V-01                                      | Livzon Mabpharm Inc                                        | protein subunit |\n| Covifenz                                  | Medicago                                                   | VLP             |\n| MVC-COV1901                               | Medigen                                                    | protein subunit |\n| Recombinant SARS-CoV-2 Vaccine (CHO Cell) | National Vaccine and Serum Institute                       | protein subunit |\n| Nuvaxovid                                 | Novavax                                                    | protein subunit |\n| IndoVac                                   | PT Bio Farma                                               | protein subunit |\n| Razi Cov Pars                             | Razi Vaccine and Serum Research Institute                  | protein subunit |\n| VidPrevtyn Beta                           | Sanofi/GSK                                                 | protein subunit |\n| COVOVAX (Novavax formulation)             | Serum Institute of India                                   | protein subunit |\n| SKYCovione                                | SK Bioscience Co Ltd                                       | protein subunit |\n| TAK-019 (Novavax formulation)             | Takeda                                                     | protein subunit |\n| SpikoGen                                  | Vaxine/CinnaGen Co.                                        | protein subunit |\n| Aurora-CoV                                | Vector State Research Center of Virology and Biotechnology | protein subunit |\n| EpiVacCorona                              | Vector State Research Center of Virology and Biotechnology | protein subunit |",
  "viper_approved_whole_virus": "| Vaccine                  | Company                                                   |\n|:-------------------------|:----------------------------------------------------------|\n| Covaxin                  | Bharat Biotech                                            |\n| KoviVac                  | Chumakov Center                                           |\n| Turkovac                 | Health Institutes of Turkey                               |\n| FAKHRAVAC (MIVAC)        | Organization of Defensive Innovation and Research         |\n| QazVac                   | Research Institute for Biological Safety Problems (RIBSP) |\n| KCONVAC                  | Shenzhen Kangtai Biological Products Co                   |\n| COVIran Barekat          | Shifa Pharmed Industrial Co                               |\n| Covilo                   | Sinopharm (Beijing)                                       |\n| Inactivated (Vero Cells) | Sinopharm (Wuhan)                                         |\n| CoronaVac                | Sinovac                                                   |\n| VLA2001                  | Valneva                                                   |",
  "viper_date_pretty": "December 2, 2022",
  "viper_num_approved_DNA": 10,
  "viper_num_approved_RNA": 9,
  "viper_num_approved_subunit": 20,
  "viper_num_approved_whole_virus": 11,
  "viper_vaccine_counts": "50",
  "viper_vax_dev_Africa": "No approved vaccines have been developed in Africa [@url:https://covid19.trackvaccines.org].",
  "viper_vax_dev_Asia": "Vaccines have been developed in 7 countries in Asia, including China (Zifivax, Anhui Zhifei Longcom; Convidecia, CanSino; Convidecia Air, CanSino; V-01, Livzon Mabpharm Inc; Recombinant SARS-CoV-2 Vaccine (CHO Cell), National Vaccine and Serum Institute; KCONVAC, Shenzhen Kangtai Biological Products Co; Covilo, Sinopharm (Beijing); Inactivated (Vero Cells), Sinopharm (Wuhan); CoronaVac, Sinovac), Iran (Noora vaccine, Bagheiat-allah University of Medical Sciences; FAKHRAVAC (MIVAC), Organization of Defensive Innovation and Research; Razi Cov Pars, Razi Vaccine and Serum Research Institute; COVIran Barekat, Shifa Pharmed Industrial Co), India (Covaxin, Bharat Biotech; iNCOVACC, Bharat Biotech; Corbevax, Biological E Limited; GEMCOVAC-19, Gennova Biopharmaceuticals Limited; Covishield (Oxford/ AstraZeneca formulation), Serum Institute of India; COVOVAX (Novavax formulation), Serum Institute of India; ZyCoV-D, Zydus Cadila), Turkey (Turkovac, Health Institutes of Turkey), Taiwan (MVC-COV1901, Medigen), Kazakhstan (QazVac, Research Institute for Biological Safety Problems (RIBSP)), and South Korea (SKYCovione, SK Bioscience Co Ltd).",
  "viper_vax_dev_Europe": "Vaccines have been developed in 5 countries in Europe, including Russia (KoviVac, Chumakov Center; Gam-COVID-Vac, Gamaleya; Sputnik Light, Gamaleya; Sputnik V, Gamaleya; Aurora-CoV, Vector State Research Center of Virology and Biotechnology; EpiVacCorona, Vector State Research Center of Virology and Biotechnology), the Netherlands (Jcovden, Janssen (Johnson & Johnson)), United Kingdom (Vaxzevria, Oxford/AstraZeneca), Germany (Comirnaty, Pfizer/BioNTech; Comirnaty Bivalent Original/Omicron BA.1, Pfizer/BioNTech; Comirnaty Bivalent Original/Omicron BA.4/BA.5, Pfizer/BioNTech), and France (VLA2001, Valneva).",
  "viper_vax_dev_North_America": "Vaccines have been developed in 3 countries in North America, including Cuba (Abdala, Center for Genetic Engineering and Biotechnology (CIGB); Soberana 02, Instituto Finlay de Vacunas Cuba; Soberana Plus, Instituto Finlay de Vacunas Cuba), Canada (Covifenz, Medicago), and the United States of America (Spikevax, Moderna; Spikevax Bivalent Original/Omicron BA.1, Moderna; Spikevax Bivalent Original/Omicron BA.4/BA.5, Moderna; Nuvaxovid, Novavax).",
  "viper_vax_dev_Oceania": "The only approved vaccine developed in Oceania is SpikoGen, which was developed by Vaxine/CinnaGen Co. in Australia [@url:https://covid19.trackvaccines.org].",
  "viper_vax_dev_South_America": "No approved vaccines have been developed in South America [@url:https://covid19.trackvaccines.org]."
}